The Relative Strength (RS) Rating for Cassava Sciences entered a new percentile Thursday, with a rise from 77 to 85.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
This unique rating measures market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history shows that the best-performing stocks typically have an RS Rating north of 80 in the early stages of their moves.
See How IBD Helps You Make More Money In Stocks
Cassava Sciences stock is not currently in a good buy position, although it has recently reversed a downtrend. See if the stock forms a new pattern now that it has cleared several key moving averages. It is closing in on the 200-day, with a recent spike in traffic. Once a new pattern is formed we can then look for a clear entry point.
Earnings Report
Cassava Sciences showed 0% EPS growth in its most recent report, while sales growth came in at 0%.
Cassava Sciences earns the No. 292 rank among its peers in the Medical-Biomed/Biotech industry group, which is currently in the top 20 of 197 groups. Arcturus Therapeutics and Catalyst Pharmaceuticals are also among the group's highest-rated stocks.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
